0R2S.LSE Stryker Corp.
- Market cap
- -
- P/E
- 58.4x
- P/B
- -
- ROE
- 15.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0R2S.LSE undervalued?
Graham numberThe Graham number of Stryker Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Stryker Corp. fundamental analysis
No fundamental analysis for Stryker Corp. yet.
Stryker Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Stryker Corp.
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial in…
Full company profileStryker Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Stryker Corp. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 11.3B | 12.4B | 13.6B | 14.9B | 14.4B | 17.1B | 18.4B | 20.5B | 22.6B | 25.1B | 25.5B |
| Gross Profit | 7.25B | 7.90B | 8.60B | 9.38B | 8.75B | 10.7B | 11.0B | 13.1B | 14.0B | 15.4B | 16.3B |
| Operating Income | 2.58B | 2.77B | 3.10B | 3.39B | 2.95B | 3.66B | 3.73B | 3.89B | 5.05B | 5.63B | 5.81B |
| EBITDA | 3.13B | 3.36B | 3.62B | 4.18B | 3.76B | 4.65B | 4.54B | 5.16B | 4.94B | 5.69B | 6.61B |
| Net Income | 1.65B | 1.02B | 3.55B | 2.08B | 1.60B | 1.99B | 2.36B | 3.17B | 2.99B | 3.25B | 3.70B |
| EPS | 4.35 | 2.68 | 9.34 | 5.48 | 4.20 | 5.22 | 6.17 | 8.25 | 7.76 | 8.49 | 9.61 |
| Balance Sheet | |||||||||||
| Total Assets | 20.4B | 22.2B | 27.2B | 30.2B | 34.3B | 34.6B | 36.9B | 39.9B | 43.0B | 47.8B | 47.2B |
| Total Liabilities | 10.9B | 12.2B | 15.5B | 17.4B | 21.2B | 19.8B | 20.3B | 21.3B | 22.3B | 25.4B | 23.8B |
| Shareholders' Equity | 9.55B | 9.97B | 11.7B | 12.8B | 13.1B | 14.9B | 16.6B | 18.6B | 20.6B | 22.4B | 23.5B |
| Cash & Short-term Investments | 3.38B | 2.79B | 3.70B | 4.43B | 3.02B | 3.02B | 1.93B | 3.05B | 4.49B | 4.10B | 3.27B |
| Total Debt | 6.91B | 7.22B | 9.86B | 11.5B | 14.4B | 12.9B | 13.5B | 13.5B | 14.3B | 16.4B | 15.4B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.92B | 1.56B | 2.61B | 2.19B | 3.28B | 3.26B | 2.62B | 3.71B | 4.24B | 5.04B | 4.40B |
| Capital Expenditure | 490M | 598M | 572M | 649M | 487M | 525M | 588M | 575M | 755M | 761M | 807M |
| Free Cash Flow | 1.43B | 961M | 2.04B | 1.54B | 2.79B | 2.74B | 2.04B | 3.14B | 3.49B | 4.28B | 3.60B |
| Ratios | |||||||||||
| ROE | 17.2% | 10.2% | 30.3% | 16.3% | 12.2% | 13.4% | 14.2% | 17.0% | 14.5% | 14.5% | 15.8% |
| ROA | 8.1% | 4.6% | 13.0% | 6.9% | 4.7% | 5.8% | 6.4% | 7.9% | 7.0% | 6.8% | 7.8% |
| Net Profit Margin | 14.5% | 8.2% | 26.1% | 14.0% | 11.1% | 11.7% | 12.8% | 15.4% | 13.2% | 12.9% | 14.5% |
| Debt to Equity | 0.72x | 0.72x | 0.84x | 0.90x | 1.10x | 0.87x | 0.81x | 0.73x | 0.69x | 0.73x | 0.66x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Stryker Corp. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- 39.6%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 1.28B | 3.36 | 39.6% |
| 2024 | USD 1.22B | 3.16 | 40.7% |
| 2023 | USD 1.14B | 2.97 | 36.0% |
| 2022 | USD 1.05B | 2.75 | 44.6% |
| 2021 | USD 950M | 2.48 | 47.6% |
| 2020 | USD 863M | 2.27 | 54.0% |
| 2019 | USD 778M | 2.05 | 37.3% |
| 2018 | USD 703M | 1.85 | 19.8% |
| 2017 | USD 636M | 1.67 | 62.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Stryker Corp.
- Insiders 5.41%
- Institutions 83.95%
- Public & others 10.65%
- Free float 346M
Stryker Corp. company profile
- Company name
- Stryker Corp.
- Ticker
- 0R2S.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 56,000
- Fiscal year end
- December
- Address
- 1941 Stryker Way, Portage, MI, United States, 49002
- Phone
- (269) 385-2600
- Website
- stryker.com
About Stryker Corp.
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Stryker Corp. management
10- Mr. Kevin A. LoboChairman & CEO · born 1965
- Mr. Spencer S. StilesPresident & COO · born 1976
- Mr. Preston W. WellsVP & CFO · born 1977
- Mr. Viju S. MenonGroup President of Global Quality & Operations · born 1968
- Mr. J. Andrew PierceGroup President of MedSurg & Neurotechnology · born 1974
- Ms. Emily BaculikVP, Chief Accounting Officer & Corporate Controller · born 1980
- Mr. Robert C. CohenCTO and VP of Global R&D - Joint Replacement
- Ms. Debra S. KingVP and Chief Digital & Information Officer · born 1972
- Mr. Nick MeadVice President of Investor Relations
- Mr. Robert S. FletcherVP & Chief Legal Officer · born 1971